Skip to main content
SpringerLink
Log in

Medically Supervised Weight Loss Programs

  • Chapter
  • First Online:
Book cover The SAGES Manual of Bariatric Surgery

  • 1600 Accesses

Abstract

Obesity is a multifactorial chronic disease affecting nearly 60 million adult Americans. Anti-obesity medications may have an important role in helping people to lose weight in the context of a lifestyle intervention program. Pharmacotherapy has shown to improve metabolic control in patients with obesity and type 2 diabetes (T2D). Due to scarce accessibility to surgery for all patients with severe obesity, there is a need for medical treatment options. Thus, it is necessary to develop effective multidisciplinary medical therapies alternative and complementary to bariatric surgery. In this chapter, we describe the role of anti-obesity drugs to treat obesity and T2D.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BID:

Two times a day

BMI:

Body mass index

CAD:

Coronary artery disease

CHF:

Congestive heart failure

ECG:

Electrocardiogram

EMA:

European medicines agency

FDA:

Food and drug administration

GLP-1:

Glucagon-like peptide 1

HTN:

Hypertension

IGT:

Impaired glucose tolerance

QD:

Once a day

T2D:

Type 2 diabetes

References

  1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491.

    Article  PubMed  Google Scholar 

  2. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8.

    Google Scholar 

  3. Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly S, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23(4):591–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161(2):218–27.

    Article  CAS  PubMed  Google Scholar 

  6. Tur JJ, Escudero AJ, Alos MM, Salinas R, Terés E, Soriano JB, et al. One year weight loss in the TRAMOMTANA study. A randomized controlled trial. Clin Endocrinol. 2013;79(6):791–9.

    Article  Google Scholar 

  7. Tur J, Alòs M, Iglesias L, Luque L, Colom A, Escudero A, et al. TRAMOMTANA (multidisciplinary treatment of morbid obesity: medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II). Endocrinol Nutr. 2011;58(6):299–307.

    Article  PubMed  Google Scholar 

  8. Shechter A. Obstructive sleep apnea and energy balance regulation: a systematic review. Sleep Med Rev. 2017;34:59–69.

    Article  PubMed  Google Scholar 

  9. van Hout GCM, van Oudheusden I, van Heck GL. Psychological profile of the morbidly obese. Obes Surg. 2004;14(5):579–88.

    Article  PubMed  Google Scholar 

  10. Kass AE, Kolko RP, Wilfley DE. Psychological treatments for eating disorders. Curr Opin Psychiatry. 2013;26(6):549–55.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the Management of Overweight and Obesity in adults. J Am Coll Cardiol. 2014;63(25):2985–3023.

    Article  PubMed  Google Scholar 

  12. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.

    Article  CAS  PubMed  Google Scholar 

  13. Zhou Y-H, Ma X-Q, Wu C, Lu J, Zhang S-S, Guo J, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Pereira RI, editor. PLoS One. 2012;7(6):e39062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Buysschaert B, Aydin S, Morelle J, Hermans MP, Jadoul M, Demoulin N. Weight loss at a high cost: orlistat-induced late-onset severe kidney disease. Diabetes Metab. 2016;42(1):62–4.

    Article  CAS  PubMed  Google Scholar 

  15. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):702.

    Article  Google Scholar 

  16. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.

    Article  CAS  PubMed  Google Scholar 

  17. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity. 2013;21(11):2163–71.

    Article  CAS  PubMed  Google Scholar 

  18. Cercato C, Roizenblatt VA, Leança CC, Segal A, Lopes Filho AP, Mancini MC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes. 2009;33(8):857–65.

    Article  CAS  Google Scholar 

  19. Search | Medscape. Drugs and diseases. 2015. Available from: http://search.medscape.com/search/?q=diethylpropion.

  20. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/Topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330–42.

    Article  CAS  PubMed  Google Scholar 

  21. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.

    Article  CAS  PubMed  Google Scholar 

  22. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.

    Article  CAS  PubMed  Google Scholar 

  23. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283(13):1703–9.

    Article  CAS  PubMed  Google Scholar 

  24. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.

    Article  CAS  PubMed  Google Scholar 

  25. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.

    Article  CAS  PubMed  Google Scholar 

  26. O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.

    Article  Google Scholar 

  27. Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Lobmaier P, editor. Cochrane Database Syst Rev. 2008;2:CD006140.

    Google Scholar 

  28. Dhillon S, Yang LPH, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653–89.

    Article  CAS  PubMed  Google Scholar 

  29. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2010;376(9741):595–605.

    Article  CAS  Google Scholar 

  30. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–43.

    Article  CAS  Google Scholar 

  31. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19(1):110–20.

    Article  CAS  PubMed  Google Scholar 

  32. Orexigen Therapeutics announces data from CORDiabetes trial for Contrave. Orexigen therapeutics announces data from CORDiabetes trial for contrave. Available from: http://www.news-medical.net/news/20100628/Orexigen-Therapeutics-announces-data-from-CORDiabetes-trial-for-Contrave.aspx.

  33. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

    Article  PubMed  Google Scholar 

  34. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443–51.

    Article  CAS  Google Scholar 

  35. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.

    Article  CAS  PubMed  Google Scholar 

  36. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgery, Digestive Diseases Institute, Cleveland Clinic Abu Dhabi, 112412, Abu Dhabi, United Arab Emirates

    Ricard Corcelles

  2. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA

    Bartolome Burguera

  3. National Diabetes and Obesity Research Institute (NDORI), Tradition, MS, USA

    Bartolome Burguera

Authors
  1. Ricard Corcelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bartolome Burguera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricard Corcelles .

Editor information

Editors and Affiliations

  1. Foregut and Bariatric Surgeon, Division of Gastrointestinal and Minimally Invasive Surgery, The Oregon Clinic, Portland, Oregon, USA

    Kevin M. Reavis

  2. Long Island Jewish Forest Hills Hospital, Department of Surgery, Hofstra-Northwell School of Medicine, Forest Hills, New York, USA

    Allison M. Barrett

  3. Institute Chief, Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

    Matthew D. Kroh

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Corcelles, R., Burguera, B. (2018). Medically Supervised Weight Loss Programs. In: Reavis, K., Barrett, A., Kroh, M. (eds) The SAGES Manual of Bariatric Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-71282-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-71282-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-71281-9

  • Online ISBN: 978-3-319-71282-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation